TEVIMBRA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Lithuania.

Active ingredients

The drug TEVIMBRA contains one active pharmaceutical ingredient (API):

1	Tislelizumab UNII 0KVO411B3N - TISLELIZUMAB
	Tislelizumab is a humanised immunoglobulin G4 (IgG4) variant monoclonal antibody against PD-1, binding to the extracellular domain of human PD-1. It competitively blocks the binding of both PD-L1 and PD-L2, inhibiting PD-1-mediated negative signalling and enhancing the functional activity in T cells in in vitro cell-based assays.
	Read more about Tislelizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TEVIMBRA Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FF09		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3045945, 3045956
FR	Base de données publique des médicaments	69201938
LT	Valstybinė vaistų kontrolės tarnyba	1097800, 1097801
US	FDA, National Drug Code	72579-121